MDRNA To Buy VC-Backed Cequent Pharma
MDRNA Inc. (Nasdaq: MRNA) has agreed to acquire Cequent Pharmaceuticals, a Cambridge, Mass.-based developer of RNAi-based treatments. The all-stock deal is valued at approximately $46 million. Cequent has raised around $17.5 million in VC funding, from Ampersand Ventures, Nexus Medical Partners, Pappas Ventures, New England Partners, Yasuda Enterprise Developmen and Novartis Option Fund.
1 April 2010•6 mins read
